AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Large ribosomal subunit protein bL28m including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Large ribosomal subunit protein bL28m therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Large ribosomal subunit protein bL28m, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Large ribosomal subunit protein bL28m. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Large ribosomal subunit protein bL28m. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Large ribosomal subunit protein bL28m includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Large ribosomal subunit protein bL28m
partner:
Reaxense
upacc:
Q13084
UPID:
RM28_HUMAN
Alternative names:
39S ribosomal protein L28, mitochondrial; Melanoma antigen p15; Melanoma-associated antigen recognized by T-lymphocytes
Alternative UPACC:
Q13084; B2RCM4; D3DU46; Q4TT39; Q96S26; Q9BQD8; Q9BR04
Background:
The Large ribosomal subunit protein bL28m, also known as 39S ribosomal protein L28, mitochondrial, Melanoma antigen p15, and Melanoma-associated antigen recognized by T-lymphocytes, plays a crucial role in the mitochondrial ribosome. Its primary function is to contribute to the synthesis of proteins within the mitochondria, a process essential for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL28m could open doors to potential therapeutic strategies. Its involvement in mitochondrial protein synthesis positions it as a key player in cellular metabolism and energy production, making it a potential target for addressing metabolic disorders and diseases related to mitochondrial dysfunction.
